JPMorgan reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline success increasingly turns into profitable commercial franchises.
The bank’s analysts, led by Jessica Fye, said several biotech companies have already moved into sustained profitability, while others are close to that stage. The report highlighted Alnylam Pharmaceuticals (ALNY), BeOne Medicines (ONC), and Ascendis Pharma (ASND) as companies that have transitioned into profitability, while Insmed (INSM) and Ionis are close to reaching that point.
JPMorgan also pointed to diversification as a major theme. Vertex Pharmaceuticals (VRTX) is expanding into renal disease, BioMarin is strengthening its rare disease portfolio through acquisitions, and Moderna (MRNA) is applying its mRNA platform to oncology. The bank also expects upcoming clinical updates, including cardiovascular outcomes trials for Ionis-partnered drugs and pivotal renal data from Vertex, to act as key sector catalysts.
JPMorgan rated Vertex, Alnylam, BeOne, United Therapeutics, Insmed, Ascendis, Jazz Pharmaceuticals, Ionis, BioMarin, and Mirum as Overweight. It assigned Neutral ratings to BioNTech, Incyte, and Halozyme, while Moderna was rated Underweight because of financial risks despite progress in oncology.
December 2026 price targets include $515 for Vertex, $420 for Alnylam, $415 for BeOne, $685 for United Therapeutics, $180 for Insmed, $100 for BioNTech, and $40 for Moderna.
Importance Level: Medium
Possible Market Effect: The report is positive for large-cap biotech sentiment, especially companies with improving profitability, diversified pipelines, and near-term clinical catalysts. The strongest market support is likely for JPMorgan’s Overweight names, while Moderna may remain under pressure due to the Underweight rating and financial-risk concerns.
Overall Market Sentiment: Neutral-to-Buy for large-cap biotech / Buy bias for JPMorgan Overweight names / Neutral-to-Sell for Moderna
Q&A
Why does JPMorgan see large-cap biotech at an inflection point? Because more companies are converting pipeline success into profitable commercial franchises and moving beyond single-product reliance.
Which biotech stocks did JPMorgan rate Overweight? JPMorgan rated Vertex, Alnylam, BeOne, United Therapeutics, Insmed, Ascendis, Jazz, Ionis, BioMarin, and Mirum as Overweight.
Why did JPMorgan rate Moderna Underweight? JPMorgan cited financial risks, even though Moderna is making progress in oncology.
What are the biggest biotech catalysts JPMorgan highlighted? Key catalysts include cardiovascular outcomes trials for Ionis-partnered drugs and pivotal renal readouts from Vertex.
Source: JPMorgan